poisar

Stocks · News reference

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Avi Kapoor

Analyst ratings and news for high-yield healthcare stocks Medtronic (3.06%), Smith & Nephew (2.74%) and GSK (3.65%).

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GSKMDTSNN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies

    Hatteras Venture Partners appointed Sir Andrew Witty as Chairman and Dr. Ned Sharpless as Managing Director of Hatteras Discovery Innovation. The firm announced the first closing of Hatteras Opportunity Fund II targeting $100 million, bringing total capital under management to over $1 billion. The new Discovery strategy aims to replicate the success of the original 2012 initiative that seeded 11 companies and contributed to two FDA-approved medicines.

    GSKUNH
  3. Hutchmed (China) Limited

    HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

    HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

    HCMGSK
  5. Delveinsight

    Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight

    The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

    MDTBSXABTNPCEINSP